Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference
22 nov. 2023 08h05 HE
|
Celcuity Inc.
MINNEAPOLIS, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its...
Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
13 nov. 2023 07h05 HE
|
Celcuity Inc.
Received FDA clearance of IND to evaluate gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer (mCRPC) Entered into a...
Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call
06 nov. 2023 07h30 HE
|
Celcuity Inc.
MINNEAPOLIS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...
Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences
01 nov. 2023 07h05 HE
|
Celcuity Inc.
MINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...
Celcuity to Host Virtual Science Day for Investors
07 sept. 2023 16h05 HE
|
Celcuity Inc.
Leading key opinion leaders to review the treatment landscape in breast and prostate cancer and the importance of targeting the PI3K/mTOR pathway in hormonally driven tumor typesDiscussion of the...
Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical Trial
22 août 2023 16h05 HE
|
Celcuity Inc.
MINNEAPOLIS, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...
Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer
22 août 2023 16h01 HE
|
Celcuity Inc.
- Received FDA clearance of IND for gedatolisib in combination with darolutamide - Virtual Science Day to be held on September 21, 2023 from 10:00 a.m. – 12:00 p.m. ET MINNEAPOLIS, Aug. 22, 2023 ...
Celcuity Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
10 août 2023 16h04 HE
|
Celcuity Inc.
Phase 3 VIKTORIA-1 clinical trial is now recruiting patients at nearly 200 sites in 20 countriesPresented updated results from Phase 1b study of gedatolisib in treatment-naïve advanced breast cancer...
Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference Call
03 août 2023 07h30 HE
|
Celcuity Inc.
MINNEAPOLIS, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it...
Celcuity to Participate in the BTIG Virtual Biotechnology Conference 2023
31 juil. 2023 08h00 HE
|
Celcuity Inc.
MINNEAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that...